Seaport Therapeutics, Inc.

Seaport Therapeutics, Inc. (SPTX) priced its initial public offering on May 1, 2026 at $18.00 per share, raising $254.9M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $954.5M. Goldman Sachs was lead-left underwriter, joined by J.P. Morgan, Leerink Partners and Citigroup and others. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

Seaport Therapeutics, Inc. is a clinical-stage company developing oral medicines for depression, anxiety and other neuropsychiatric disorders. It applies its proprietary Glyph platform to overcome limits such as high first-pass metabolism and low bioavailability of established mechanisms.

Status

IPO

Ticker

SPTX

Exchange

Nasdaq Global Select

Priced

May 1, 2026

IPO price

$18.00

Raised

$254.9M

Market cap at IPO price

$954.5M

First filed

Apr 10, 2026

Underwriters

Goldman Sachs, J.P. Morgan, Leerink Partners, Citigroup and Stifel

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.